Barbadin (C007B-336661)

Barbadin is a novel and selective β-arrestin/β2-adaptin interaction inhibitor, has IC 50 values of 19.1 μM for β-arrestin1 and 15.6 μM for β-arrestin2. Barbadin blocks agonist-promoted endocytosis of the prototypical β2-adrenergic, V2-Vasotocin and angiotensin-II type-1 receptors. Barbadin can induce apoptosisIn VitroBarbadin (4 h) treatment reduces cell viability and induces apoptosis. Barbadin (2 h) treatment arrests breast cancer cells in G0/G1 phase. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Apoptosis AnalysisCell Line: MDA MB-231 cells Concentration: Incubation Time: 4 hours Result: Exhibited morphological characteristics of apoptosis including shrinkage, rounding and detachment, the percent of cell viability was reduced to 69.1% and apoptosis was developed in 29.9% of cells starved with EBSS (Earle’s balanced salt solution). Cell Cycle AnalysisCell Line: MDA MB-231 cells Concentration: Incubation Time: 2 hours Result: Arrested 63.7% of cells in G0/G1 phase.IC50& Target:IC50: 19.1 μM (β-arrestin1),15.6 μM (β-arrestin2).

Specifications and Purity: 10mM in DMSO

Molecular Formula: C19H15N3OS

Molecular Weight: 333.41